We have developed a significant Intellectual Property (IP) portfolio that covers our technology platforms, protects our products in development, and blocks others seeking to imitate our approach. We intend to continue to build this portfolio.

Our patents and patent applications cover, among other things:

	Oral delivery of Insulin,
	Oral delivery of Hepatitis B vaccine
	Selective targeting of APCs with our proprietary fusion protein employed in the development of AIDS therapeutic vaccine
	Selective targeting of APCs with our proprietary fusion protein employed in the development of Multiple Sclerosis
	Proprietary genetically modified Adeno Associated Viral vectors
	Targeted therapy employing shRNA –AAV in the treatment of metastatic Breast cancer
	Targeted therapy employing miRNA –AAV in the treatment of metastatic Liver cancer
	Targeted therapy employing novel humanized monoclonal antibody in the treatment of Colon cancer
	Targeted therapy employing novel humanized monoclonal antibody in the treatment of Multiple myeloma
	Targeted therapy employing novel humanized monoclonal antibody in the treatment of Non-Hodgkin’s Lymphoma
	Novel, proprietary and receptor specific drug delivery formulations employing novel carrier systems to deliver protein and peptide based drugs through oral and transdermal methods of administration